Emre BAHÇİVAN, Burak DİK, Devran COŞKUN, Kamil ÜNEY

Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats

Background/aim: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. Materials and methods: In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+highdose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. Results: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. Conclusion: The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5′-monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold.Key words: Benzimidazole, HOMA-β, diabetes, antiabetic, rat

PDF

___

1. Dik B, Bahcivan E, Eser Faki H, Uney K. Combined treatment with interleukin-1 and tumor necrosis factor-alpha antagonists improve type 2 diabetes in rats. Canadian Journal of Physiology and Pharmacology 2018; 96: 751-756. doi: 10.1139/cjpp-2017-0769
2. Kitada M, Ogura Y, Monno I, Koya D. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function. Frontiers in Endocrinology 2019; 10: 1-12. doi: 10.3389/fendo.2019.00187
3. Desjardins EM, Steinberg GR. Emerging role of AMPK in brown and beige adipose tissue (bat): implications for obesity, insulin resistance, and type 2 diabetes. Current Diabetes Reports 2018; 18: 1-9. doi: 10.1007/s11892-018-1049-6
4. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014; 7: 241-253. doi: 10.2147/DMSO.S43731
5. Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF et al. Structural basis of AMPK regulation by small molecule activators. Nature Communications 2013; 4 (3017): 1-10. doi: 10.1038/ncomms4017
6. Jeon SM. Regulation and function of AMPK in physiology and diseases. Experimental and Molecular Medicine 2016; 48 (e245): 1-13. doi: 10.1038/emm.2016.81
7. Chellappan DK, Yap WS, Bt Ahmad Suhaimi NA, Gupta G, Dua K. Current therapies and targets for type 2 diabetes mellitus. Panminerva Medica 2018; 60: 117-131. doi: 10.23736/ S0031-0808.18.03455-9
8. Casanova E, Salvado J, Crescenti A, Gibert-Ramos A. Epigallocatechin gallate modulates muscle homeostasis in type 2 diabetes and obesity by targeting energetic and redox pathways: a narrative review. International Journal of Molecular Sciences 2019; 20 (3): 1-16. doi: 10.3390/ijms20030532
9. Kim J, Yang G, Kim Y, Kim J, Ha J. AMPK activators: mechanisms of action and physiological activities. Experimental and Molecular Medicine 2016; 48 (e224): 1-12. doi: 10.1038/emm.2016.16
10. Lai YC, Kviklyte S, Vertommen D, Lantier L, Foretz M et al. A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators. Biochemical Journal 2014; 460: 363-375. doi: 10.1042/BJ20131673
11. Sekar V, Mani S, Malarvizhi R, Nithya P, Vasanthi HR. Antidiabetic effect of mangiferin in combination with oral hypoglycemic agents metformin and gliclazide. Phytomedicine 2019; 59 (152901): 1-11. doi: 10.1016/j.phymed.2019.152901
12. Bahne E, Sun EWL, Young RL, Hansen M, Sonne DP et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight 2018; 3 (23): 1-15. doi: 10.1172/jci.insight.93936
13. Xu C, Li XF, Tian HY, Shi HJ, Zhang DD et al. Metformin improves the glucose homeostasis of Wuchang bream fed highcarbohydrate diets: a dynamic study. Endocrine Connections 2019; 8: 182-194. doi: 10.1530/EC-18-0517
14. Zhou G, Myers R, Li Y, Chen Y, Shen X et al. Role of AMPactivated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 2001; 108: 1167-1174. doi: 10.1172/JCI13505
15. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. American Journal of Physiology - Endocrinology and Metabolism 2006; 291: 175-181. doi: 10.1152/ajpendo.00453.2005
16. Toraj AJ, Khadije NG, Bahare L Hamid AM, Nayeb Ali A et al. Evaluating effect of albendazole on Trichuris trichiura infection: a systematic review article. Iranian Journal of Parasitology 2016; 11: 441-447
17. Wildenberg ME, Levin AD, Ceroni A, Guo Z, Koelink PJ et al. Benzimidazoles promote anti-tnf mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model. Journal of Crohn’s and Colitis 2017; 11: 1480- 1490. doi: 1190. 10.1093/ecco-jcc/jjx104
18. Satoh H. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Current Pharmaceutical Design 2013; 19: 67-75. doi: 10.2174/13816128130110
19. Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Medical Hypotheses 2009; 73: 29- 32. doi: 10.1016/j.mehy.2009.02.010
20. Hao S, Sun J, Tian X, Sun X, Zhang Z et al. Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects. Journal of Pharmacy and Pharmacology 2014; 66: 1133-1139. doi: 10.1111/jphp.12237
21. Benchamana A, Mori H, MacDougald OA, Soodvilai S. Regulation of adipocyte differentiation and metabolism by lansoprazole. Life Sciences 2019; 239: 1-20. doi: 10.1016/j. lfs.2019.116897
22. Gamil NM, Abd El Fattah MA, Ahmed MA, Maklad YA, Gamal el Din AA et al. Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet‐fed streptozotocin‐treated diabetic rats. Journal of Biochemical and Molecular Toxicology 2020; 34 (e22451): 1-14. doi: 10.1002/jbt.22451
23. Kaur R, Sodhi RK, Aggarwal N, Kaur J, Jain UK. Renoprotective effect of lansoprazole in streptozotocin-induced diabetic nephropathy in wistar rats. Naunyn-Schmiedeberg’s Archives of Pharmacology 2016; 389: 73-85. doi: 10.1007/s00210-015- 1182-6
24. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocintreated rat: a model for type 2 diabetes and pharmacological screening. Pharmacological Research 2005; 52: 313-320. doi: 10.1016/j.phrs.2005.05.004
25. Liu Y, Deng J, Fan D. Ginsenoside Rk3 ameliorates high-fatdiet/streptozocin induced type 2 diabetes mellitus in mice via the AMPK/Akt signaling pathway. Food and Function 2019; 10: 2538-2551. doi: 10.1039/c9fo00095j
26. Bharadwaj SS, Poojary B, Nandish SKM, Kengaiah J, Kirana MP et al. Efficient synthesis and in silico studies of the benzimidazole hybrid scaffold with the quinolinyloxadiazole skeleton with potential alpha-glucosidase inhibitory, anticoagulant, and antiplatelet activities for type-ii diabetes mellitus management and treating thrombotic disorders. ACS Omega 2018; 3 (10): 12562-12574. doi: 10.1021/acsomega.8b01476
27. Goebel M, Wolber G, Markt P, Staels B, Unger T et al. Characterization of new PPARγ agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. Bioorganic and Medicinal Chemistry 2010; 18: 5885-5895. doi: 10.1016/j. bmc.2010.06.102
28. El Bakri Y, Anouar EH, Marmouzi I, Sayah K, Ramli Y et al. Potential antidiabetic activity and molecular docking studies of novel synthesized 3.6-dimethyl-5-oxo-pyrido[3,4-f][1,2,4] triazepino[2,3-a]benzimidazole and 10-amino-2-methyl-4- oxo pyrimido[1,2-a]benzimidazole derivatives. Journal of Molecular Modeling 2018; 24 (7): 1-10. doi: 10.1007/s00894- 018-3705-9
29. Brown AE, Dibnah B, Fisher E, Newton JL, Walker M. Pharmacological activation of AMPK and glucose uptake in cultured human skeletal muscle cells from patients with ME/CFS. Bioscience Reports 2018; 38: 1-7. doi: 10.1042/ BSR20180242
30. Bultot L, Jensen TE, Lai YC, Madsen AL, Collodet C et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism 2016; 311 (4): 706-719. doi: 10.1152/ajpendo.00237.2016
31. Loos JA, Cumino AC. In vitro anti-echinococcal and metabolic effects of metformin involve activation of amp-activated protein kinase in larval stages of Echinococcus granulosus. PLoS One 2015; 10 (5): 1-23. doi: 10.1371/journal.pone.0126009
32. Ihedioha JI, Noel-Uneke OA, Ihedioha TE. Reference values for the serum lipid profile of albino rats (Rattus norvegicus) of varied ages and sexes. Comparative Clinical Pathology 2013; 22: 93-99. doi: 10.1007/s00580-011-1372-7
33. Boehm O, Zur B, Koch A, Tran N, Freyenhagen R et al. Clinical chemistry reference database for wistar rats and C57/BL6 mice. Biological Chemistry 2007; 388: 547-554. doi: 10.1515/ BC.2007.061
34. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba B et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European Journal of Endocrinology 2003; 149: 331-336. doi: 10.1530/ eje.0.1490331
35. Fujita H, Fujishima H, Morii T, Koshimura J, Narita T et al. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochemical and Biophysical Research Communications 2002; 298: 345-349. doi: 10.1016/s0006- 291x(02)02464-6
36. Jung HS, Youn BS, Cho YM, Yu KY, Park HJ et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005; 54: 314-320. doi: 10.1016/j.metabol.2004.05.019
37. Moser C, Vickers SP, Brammer R, Cheetham SC, Drewe J. Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice. Phytomedicine 2014; 21: 1382-1389. doi: 10.1016/j.phymed.2014.06.002
38. Jiang SJ, Dong H, Li JB, Xu LJ, Zou X et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World Journal of Gastroenterology 2015; 21: 7777-7785. doi: 10.3748/wjg.v21.i25.7777
39. Katwan OJ, Alghamdi F, Almabrouk TA, Mancini SJ, Kennedy S et al. AMP-activated protein kinase complexes containing the β2 regulatory subunit are up-regulated during and contribute to adipogenesis. Biochemical Journal 2019; 476: 1725-1740. doi: 10.1042/BCJ20180714
40. Shingalapur RV, Hosamani KM, Keri RS, Hugar MH. Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. European Journal of Endocrinology 2010; 45: 1753-1759. doi: 10.1016/j.ejmech.2010.01.007
41. Fujimura T, Sakuma H, Konishi S, Oe T, Hosogai N et al. FK614, a novel peroxisome proliferator-activated receptor γ modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. Journal of Pharmacological Sciences 2005; 99 (4): 342-352. doi: 10.1254/jphs.fp0050578